Nintedanib for treating idiopathic pulmonary fibrosis in people with a forced vital capacity above 80% predicted (part-review of technology appraisal guidance 379)
Report published in 2022 by
Keith Cooper 
,
Lorna Hazell,
Asyl Hawa,
Joanna Picot,
Fay Chinnery,
David Alexander Scott,
Jonathan Shepherd
,
Lorna Hazell,
Asyl Hawa,
Joanna Picot,
Fay Chinnery,
David Alexander Scott,
Jonathan Shepherd
